share_log

Daré Bioscience Announces Publication In Contraception Of Efficacy And Safety Findings From A Pre-Pivotal Postcoital Test Study Of Ovaprene: An Investigational Hormone-Free Monthly Intravaginal Contraceptive

Daré Bioscience Announces Publication In Contraception Of Efficacy And Safety Findings From A Pre-Pivotal Postcoital Test Study Of Ovaprene: An Investigational Hormone-Free Monthly Intravaginal Contraceptive

DaréBioscience宣布在《避孕》杂志上发表一项针对Ovaprene的关键性交后测试研究的功效和安全性结果:一种研究性无激素的月度阴道内避孕药
Benzinga ·  04/11 08:15
Published data shows that Ovaprene was safe and effective in a postcoital test study of 33 women
已公布的数据显示,在一项针对33名女性的性交后测试研究中,Ovaprene是安全有效的
Pivotal Phase 3 contraceptive efficacy clinical study of Ovaprene currently enrolling
Ovaprene的关键性3期避孕功效临床研究目前正在报名
Ovaprene has the potential to be the first FDA-approved hormone-free monthly intravaginal contraceptive for women
Ovaprene有可能成为美国食品药品管理局批准的第一种女性每月无激素阴道内避孕药
SAN DIEGO, April 11, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women's health innovation, today announced the publication of data from the postcoital test clinical study of Ovaprene in two original research articles in the journal Contraception.
圣地亚哥,2024年4月11日(GLOBE NEWSWIRE)——女性健康创新的领导者达瑞生物科学公司(纳斯达克股票代码:DARE)今天宣布,在该期刊的两篇原创研究文章中公布了Ovaprene性交后测试临床研究的数据 避孕。
Publication Details:
出版物详情:
Mauck, et al. "Successful postcoital testing of Ovaprene: An investigational non- hormonal monthly vaginal contraceptive...
莫克等人“Ovaprene的成...
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发